For example, anti-PD-1 monotherapy has been shown to be unable to improve survival outcomes for non-small cell lung cancer (NSCLC) patients with EGFR mutations, even in patients with high PD-L1 expression [21]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.